メンバー

スタッフ

English Information

はぎわら やすひろ

萩原 康博助教    

HAGIWARA Yasuhiro

健康科学・看護学専攻 生物統計学分野

hagiwara [at] epistat.m.u-tokyo.ac.jp

研究

医療統計学の研究と実践をしています。
医療統計学の研究としては、(1)臨床研究や疫学研究における因果推論手法と(2)HEOR (Health Economics and Outcomes Research) での統計手法について研究しています。
これまで取り組んできた具体的な研究テーマは以下の通りです。

- 臨床研究や疫学研究における因果推論手法
・生存時間アウトカムに対する時間依存性治療の効果推定
(Hagiwara et al. Biometrics. 2020. Hagiwara et al. Biometrics. 2021.)
・恒等・対数リンク関数を用いた二値アウトカムのリスク差とリスク比の推定
(Hagiwara et al. Am J Epidemiol. 2018. Fuyama et al. Emerg Themes Epidemiol. 2021. Hagiwara et al. submitted.)

- HEORでの統計手法
・医療経済評価における非選好型尺度からQOL値へのマッピング手法
(Hagiwara et al. Value Health. 2020. Hagiwara et al. Health Qual Life Outcomes. 2020. Hagiwara et al. Value Health. 2023. Hagiwara. Med Decis Making. 2023+. )
・医療技術の価値にもとづく価格設定(value-based pricing)における推測と決定分析
(Hagiwara et al. Med Decis Making. 2022.)

医療統計学の実践としては、がん領域を中心に様々な臨床研究に医療統計家として参加しています。
特に健康関連QOL研究などのヘルスアウトカム研究には医療統計家の役割をこえて積極的に取り組み、論文を発表してきました(Hagiwara et al. ESMO Open. 2017. Hagiwara et al. Eur J Cancer. 2018. Hagiwara et al. Pharmacoeconomics. 2018. Hagiwara et al. Breast Cancer Res Treat. 2021. Izumi et al. Health Qual Life Outcomes. 2023.)。
今後も医療統計家として医療の発展に貢献していきます。

経歴

2010.4 東京大学文科三類 入学
2014.3 東京大学医学部健康総合科学科 卒業 学士(保健学)
2016.3 東京大学大学院医学系研究科公共健康医学専攻専門職学位課程 修了 公衆衛生学修士(専門職)
2019.3 東京大学大学院医学系研究科健康科学・看護学専攻博士後期課程 修了 博士(保健学)
2019.4 東京大学大学院医学系研究科健康科学・看護学専攻生物統計学分野 助教

活動

所属学会:
-日本計量生物学会(正会員)
-International Biometric Society(会員)
-International Society of Pharmacoeconomics and Outcomes Research(会員)
-QOL-PRO研究会(正会員)

受賞歴:
-東京大学 大学院医学系研究科 公共健康医学専攻 平成27年度課題研究発表 優秀賞
-ISPOR (International Society for Pharmacoeconomics and Outcome Research) Asia Pacific 2018 Best Student Poster Research Presentation
-2021年度 日本計量生物学会 奨励賞

競争的研究資金:
-日本学術振興会 科学研究費助成事業 研究活動スタート支援 2019年8月~2023年3月
(医療経済評価における非選好型尺度からQOL値へのマッピング手法に関する基礎的研究、19K24193、研究代表者)
-日本学術振興会 科学研究費助成事業 基盤研究(B)2021年4月~2022年3月
(地域住民の認知症支援意識を高めるVR・ゲーミフィケーション統合プログラムの開発、19H03956、研究分担者)
-日本学術振興会 科学研究費助成事業 若手研究 2022年4月~2024年3月
(臨床試験で測定された経時QOL値データの医療経済評価を目的とした統計解析、22K17858、研究代表者)

学外活動:
-公益財団法人パブリックヘルスリサーチセンター ヘルスアウトカムリサーチ支援事業 運営委員(2017年10月~)
-日本計量生物学会 企画委員(2021年~2023)
-QOL-PRO研究会 評議員(2022年~)
-日本乳癌学会 診療ガイドライン委員会 QoL・医療経済評価小委員会 委員(2022年~)

  1. Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2023. doi: 10.1007/s10549-023-07099-4. Online ahead of print.
  2. Fukuhara H, Hagiwara Y, Oba K, Inoue K. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan. Photodiagnosis Photodyn Ther. 2023;103758. doi: 10.1016/j.pdpdt.2023.103758.
  3. Hagiwara Y. Using a sample size calculation framework for clinical prediction models when developing and selecting mapping algorithms based on linear regression. Med Decis Making. 2023. doi: 10.1177/0272989X231188134. Online ahead of print.
  4. Suzuki Y, Iwamoto T, Uno M, Hatono M, Kajiwara Y, Takahashi Y, Kochi M, Shien T, Kikawa Y, Uemura Y, Hagiwara Y, Yamamoto S, Taira N, Doihara H, Toyooka S. Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer. Breast Cancer. 2023. doi: 10.1007/s12282-023-01480-3. Online ahead of print.
  5. Izumi S, Hagiwara Y, Matsuyama Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L. Health Qual Life Outcomes. 2023;21:3.
  6. Okada A, Yamada G, Kimura T, Hagiwara Y, Yamaguchi S, Kurakawa KI, Nangaku M, Yamauchi T, Matsuyama Y, Kadowaki T. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. J Diabetes Investig. 2022. https://doi.org/10.1111/jdi.13966 Online ahead of print.
  7. Matsumoto H, Hagiwara Y, Yamamoto-Mitani N, Igarashi A. A randomized control trial for ReDeSign: A dementia-friendly mobile microlearning training for store workers in Japan. Gerontologist. 2022 Dec 12;gnac182. doi: 10.1093/geront/gnac182. Online ahead of print.
  8. Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PLoS One. 2022;17:e0278344.
  9. Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Gradient boosted tree approaches for mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 onto 5-level version of EQ-5D index for patients with cancer. Value Health. 2022. doi: 10.1016/j.jval.2022.07.020. Online ahead of print.
  10. Fujita S, Hagiwara A, Takei N, Fukunaga I, Hagiwara Y, Ogawa T, Hatano T, Rettmann D, Banerjee S, Hwang K, Amemiya S, Kamagata K, Hattori N, Abe O, Aoki S. Rigid real-time prospective motion-corrected three-dimensional multiparametric mapping of the human brain. Neuroimage. 2022;119176. doi: 10.1016/j.neuroimage.2022.119176. Online ahead of print.
  11. Fujita S, Cencini M, Buonincontri G, Takei N, Schulte RF, Fukunaga I, Uchida W, Hagiwara A, Kamagata K, Hagiwara Y, Matsuyama Y, Abe O, Tosetti M, Aoki S. Simultaneous Relaxometry and Morphometry of Human Brain Structures with Three-dimensional Magnetic Resonance Fingerprinting: A Multicenter, Multiplatform, Multi-field-strength Study. Cereb Cortex. 2022. doi: 10.1093/cercor/bhab259. Online ahead of print.
  12. Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M. Cost-effectiveness of trastuzumab with or without chemotherapy as adjuvant therapy in HER2-positive elderly breast cancer patients: a randomized, open-label clinical trial, the RESPECT trial. Clin Drug Investig. 2022. doi: 10.1007/s40261-022-01124-y. Online ahead of print.
  13. Hagiwara Y, Shiroiwa T. Estimating Value-Based Price and Quantifying Uncertainty Around It in Health Technology Assessment: Frequentist and Bayesian Approaches. Med Decis Making. 2022 Feb 17. doi: 10.1177/0272989X221079554. Online ahead of print.
  14. Matsumoto H, Igarashi A, Hagiwara Y, Yamamoto-Mitani N. Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers. Contemp Clin Trials Commun. 2022;26:100896.
  15. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg. 2021;S0278-2391(21)01511-1. doi: 10.1016/j.joms.2021.12.007. Online ahead of print.
  16. Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial. Qual Life Res. 2022 Jan 4. doi: 10.1007/s11136-021-03074-y. Online ahead of print.
  17. Fuyama K, Hagiwara Y, Matsuyama Y. A simulation study of regression approaches for estimating risk ratios in the presence of multiple confounders. Emerg Themes Epidemiol. 2021;18:18.
  18. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Non-parametric approach for frequentist multiple imputation in survival analysis with missing covariates. Stat Methods Med Res. 2021; 30(7): 1691-1707.
  19. Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Res Treat. 2021. https://doi.org/10.1007/s10549-021-06253-0
  20. Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized controlled trial of paper-based at a hospital versus continual electronic patient-Reported outcomes at home for metastatic cancer patients: does electronic measurement at home detect patients' health status in greater detail? Med Decis Making. 2021. doi:10.1177/0272989X211010171.
  21. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. Am J Gastroenterol. 2021. doi: 10.14309/ajg.0000000000001256.
  22. Hirose N, Morita K, Jo T, Hagiwara Y, Matsui H, Fushimi K, Yasunaga H. Differences in disease severity and in-hospital mortality in patients hospitalised for pneumonia with and without intellectual disabilities: A matched-pair retrospective cohort study using nationwide in-patient database. J Intellect Dev Disabil. Online ahead of print.
  23. Takeuchi Y, Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database. Diabetes Obes Metab. 2021; 23(6): 1379-1388.
  24. Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Health Qual Life Outcomes. 2020;18:306.
  25. Yamada G, Hagiwara Y, Kimura T, Takeuchi Y, Oba K, Masuda K, Matsuyama Y. Impact of body weight gain on the incidence of non-alcoholic fatty liver disease in non-obese Japanese individuals. Am J Gastroenterol. 2021; 116(4): 733-740.
  26. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? A response from a missing data perspective. Value Health. 2020;23:1218–1224.
  27. Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2020. doi: 10.1111/biom.13296. Online ahead of print.
  28. Hagiwara Y, Shinozaki T, Matsuyama Y. G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome. Biometrics. 2020;76:799–810.
  29. Yoshida T, Uchino S, Sasabuchi Y, Hagiwara Y, the AFTER-ICU study group. Prognostic impact of sustained new-onset atrial fibrillation in critically ill patients. Intensive Care Med. 2020;46:27–35.
  30. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019;30:259-265.
  31. Ishimaru M, Matsui H, Ono S, Hagiwara Y, Morita K, Yasunaga H. Preoperative oral care and effect on postoperative complications after major cancer surgery. Br J Surg. 2018;105:1688-1696.
  32. Hagiwara Y, Fukuda M, Matsuyama Y. The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol. 2018;187:2481-2490.
  33. Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomized phase III trial (JASPAC 01). Eur J Cancer. 2018;93:79-88.
  34. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analyzed with propensity score weighting. Liver Int. 2018;38:484-493.
  35. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Patient-reported outcome results from the open-label randomized phase III SELECT BC trial evaluating first-line S-1 therapy for metastatic breast cancer. Oncology. 2018;94:107-115
  36. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC Cancer. 2017;17:773.
  37. Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215-223.
  38. Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y for the SELECT BC Study Group. The impact of treatment preferences in second-line chemotherapy on the prognosis of HER2-negative metastatic breast cancer. Oncology. 2017;93:315-322.
  39. Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
  40. Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open. 2017;2:e000151.
  41. Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79:813-823.
  42. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017;26:445-453.

論文(和文)

  1. 萩原康博.反事実予測モデルと個別化治療効果.臨床評価.2023:51;269–279.

  1. Takeuchi Y, Hagiwara Y, Matsuyama Y. Marginal structural Cox models in nested case-control studies with time-varying treatments. 42nd Conference of the International Society for Clinical Biostatistics. Online. Jul 2021.
  2. Takeuchi Y. Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y, Risk of Sodium-Glucose Cotransporter-2 Inhibitor on the Incidence of Urinary Tract Infection among Diabetic Patients in Japan: A Nationwide Cohort Study (poster presentation). ICPE All Access. Online. Sep 2020.
  3. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
  4. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Multiple imputation for survival analysis with missing covariates using non-parametric estimation. 12th Asian Conference on Pharmacoepidemiology and 25th Japanese Conference on Pharmacoepidemiology joint meeting. Kyoto. Oct 2019.
  5. Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  6. Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  7. Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
  8. Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
  9. Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis. European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018. Barcelona, Spain. June 2018.
  10. Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.
  11. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN161.
  12. Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN204.
  13. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H. Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial. International Society for Quality of Life Research 23rd Annual Conference, Copenhagen, Denmark, October 21. Abstract 2029.
  14. Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H. Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study. American Society for Clinical Oncology annual meeting 2016, Chicago, US, June, 2016. J Clin Oncol. 2016; 34(suppl; abstr 4107).
  15. Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
  16. Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H. Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial. International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress, Milan, Italy, November 9, 2015. Abstract PCN210.

学会発表(国内)

  1. 萩原康博.効果の異質性に対する予測によるアプローチ:観察コホート研究での実践.2023年度統計関連学会連合大会,京都+オンライン, 2023/9/5.
  2. 萩原康博,松山裕.修正Poisson 回帰における適合度検定:1 を超える当てはめ値の影響.2023年度日本計量生物学会年会,札幌+オンライン,2023/4/20.
  3. 萩原康博.反事実予測モデルと個別化治療効果.ヘルスデータサイエンス学会第1回学術集会,オンライン,2022/11/26.
  4. 萩原康博,白岩健,平成人,川原拓也,此村恵子,能登真一,福田敬,下妻晃二郎.EORTC QLQ-C30からEQ-5D-5L indexへのマッピングに対する勾配ブースティング木の適用.第17回国際医薬経済・アウトカム研究学会日本部会学術集会,オンライン,2022/10/21.
  5. 萩原康博,白岩健.医療技術評価における価値にもとづく価格の推定とその不確実性の定量化.ISPOR日本部会第16回学術集会,オンライン,2022/3/31.
  6. 萩原康博.構造ネスト制限付き平均損失時間モデルのg推定法による時間依存性治療の効果推定.2021年度統計関連連合大会,オンライン,2021/9/7.
  7. 萩原康博.動的治療レジメンにもとづく臨床試験のエスティマンド.2021年度統計関連連合大会,オンライン,2021/9/7.
  8. 河口義邦,長谷川潔,萩原康博,Bellis MD、Famularo S,Panettieri E,松山裕,建石良介,市川智章,國土貴嗣,泉並木,久保正二,坂本享宇,椎名秀一朗,高山忠利,中島収,村上卓道,Vauthey JN,Giuliante F,Carlis LD,Romano F,Ruzzenente A,Guglielmi A,工藤正俊、國土典宏.肝細胞癌の腫瘍径・腫瘍個数による手術、TACE、焼灼療法の生存予測(日本肝癌研究会追跡調査).第57回日本肝癌研究会,鹿児島(ハイブリッド),2021/7/23.
  9. ⽯井健夫,多川⿑,久雄⼀,萩原康博,松⼭裕,有村義宏,⽥村功⼀,⼤⼭邦雄.透析患者の塩分量と予後との関連の調査.第100回神奈川腎研究会,横浜,2021/5/29.
  10. 布山佳菜子,萩原康博,松山裕.疫学研究における修正ポアソン回帰によるリスク比推定.2020年度統計関連連合大会,オンライン,2020/9/11.
  11. 萩原康博.構造ネスト制限付き平均損失時間モデルのg推定法による治療変更を伴うランダム化比較試験データの解析.2020年度統計関連連合大会,オンライン,2020/9/10.
  12. 山内理海,設楽紘平,山中竹春,傳田忠道,辻靖,小松嘉人,小林良充,古瀬 純司,加藤健志,沖英次,安藤高志,萩原康博,大橋靖雄,吉野孝之.REVERCE: randomized phase II study of regorafenib followed by cetuximab vs. reverse sequence for colorectal cancer.第16回日本臨床腫瘍学会学術集会.神戸.2018年7月.
  13. 萩原康博,福田武蔵,松山裕.Modified Least-Squares回帰による妥当なリスク差推定に必要な1交絡変数当たりのイベント数.2018年度日本計量生物学会年会,東京,2018/3/30.
  14. 遠山竜也,渡辺隆紀,下妻晃二郎,白岩健,福田敬,毛利光子,上村夕香理,川原拓也,萩原康博,大橋靖雄,向井博文.SELECT BC試験におけるHRQOLと医療経済評価.第23回日本乳癌学会学術総会,東京,2015/7/2.
  15. 萩原康博,木原清敬,松山裕,大橋靖雄.質調整生存時間の効用値欠測と生存時間打ち切りに対する感度解析:進行膵癌臨床試験データへの適用.2014年度日本計量生物学会年会,東京,2014/5/24.

  1. Hagiwara Y. Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models. PeSeTo International Symposium on Public Health 2016, Tokyo, Japan, March 15, 2016.

シンポジウム(国内)

  1. 萩原康博.RESPECTでの認知機能評価について.第14回CSP-HOR年会,東京,2022/10/15.
  2. 萩原康博.QOL値へのマッピング手法の現状と課題.CHEERS特別シンポジウム:HTA における QOL 評価の意義と課題,京都,2022/3/5.
  3. 萩原康博.G-estimation:治療の影響を受ける交絡変数の調整.NDB・DPCデータベース研究人材育成<短期集中セミナー>,東京,2019/8/6.
  4. 萩原康博,大橋靖雄.QOLの統計的評価:最近の成果から.第89回QOL研究会,東京,2017/9/17.
  5. 萩原康博.SELECT BC のQOL、医療経済評価およびEQ-5Dについて: EQ-5Dへの有害事象の影響.第11回CSP-HOR年会,東京,2017/7/1.
  6. 萩原康博.QALYの解析に関わる統計的な問題.第10回CSP-HOR年会,東京,2016/8/20.
  7. 萩原康博.臨床試験においてMIDをendpointにおいた場合の課題:Time to Deterioration解析を中心に.QOL/PRO研究会 第5回研究セミナー,草津,2015/7/11.

TOP